RNA — Atrium Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $235.32m
- $235.32m
- $18.62m
Annual cashflow statement for Atrium Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -6.38 | -25.1 | -49.5 |
| Depreciation | |||
| Deferred Taxes | |||
| Non-Cash Items | 2.7 | 3.38 | 8.39 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | 59.9 | -12.9 | -0.2 |
| Change in Accounts Receivable | |||
| Change in Prepaid Expenses | |||
| Change in Other Assets | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Change in Other Liabilities | |||
| Net Change in Other Assets & Liabilities | |||
| Cash from Operating Activities | 56.4 | -22.6 | -41.1 |
| Capital Expenditures | -0.32 | -0.266 | -1.45 |
| Purchase of Fixed Assets | |||
| Cash from Investing Activities | -0.32 | -0.266 | -1.45 |
| Financing Cash Flow Items | -56.1 | 22.8 | 42.6 |
| Other Financing Cash Flow | |||
| Cash from Financing Activities | -56.1 | 22.8 | 42.6 |
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | 0 | 0 | 0 |